Over a month ago |
Syndicate
| ShowHide Related Items >><< - 04/24/23
- LumiraDx receives noncompliance notification from Nasdaq
- 04/06/23
- LumiraDx to further reduce global workforce by 40%
- 02/27/23
- LumiraDx gets FDA EUA amendment for SARS-CoV-2 RNA STAR Complete test kit
- 02/06/23
- LumiraDx receives FDA EUA, U.K. CTDA approval for LumiraDx SARS-CoV-2 assay
- 04/07/23 Raymond James
- LumiraDx price target lowered to $1.50 from $2 at Raymond James
- 12/19/22 Goldman Sachs
- LumiraDx initiated with a Neutral at Goldman Sachs
- 08/19/22 BTIG
- LumiraDx price target lowered to $4 from $7 at BTIG
- 05/12/22 Ladenburg
- LumiraDx price target lowered to $14 from $15.25 at Ladenburg
- 03/21/23
- LumiraDx reports Q4 adjusted EPS (12c), consensus (20c)
- 11/09/22
- LumiraDx reports Q3 EPS (47c), consensus (26c)
|
Hot Stocks
|
LumiraDx announced that… LumiraDx announced that it has received notification from Nasdaq that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450 for continued listing on the Nasdaq Global Market, since the closing bid price for the company's common shares on the Nasdaq Global Market was below $1.00 for 30 consecutive trading days. Nasdaq Listing Rule 5450 requires the common shares to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810 provides that failure to meet such requirement exists if the deficiency continues for a period of 30 consecutive business days. ShowHide Related Items >><< - 04/06/23
- LumiraDx to further reduce global workforce by 40%
- 02/27/23
- LumiraDx gets FDA EUA amendment for SARS-CoV-2 RNA STAR Complete test kit
- 02/06/23
- LumiraDx receives FDA EUA, U.K. CTDA approval for LumiraDx SARS-CoV-2 assay
- 01/31/23
- LumiraDx receives noncompliance notification from Nasdaq
- 04/07/23 Raymond James
- LumiraDx price target lowered to $1.50 from $2 at Raymond James
- 12/19/22 Goldman Sachs
- LumiraDx initiated with a Neutral at Goldman Sachs
- 08/19/22 BTIG
- LumiraDx price target lowered to $4 from $7 at BTIG
- 05/12/22 Ladenburg
- LumiraDx price target lowered to $14 from $15.25 at Ladenburg
- 03/21/23
- LumiraDx reports Q4 adjusted EPS (12c), consensus (20c)
- 11/09/22
- LumiraDx reports Q3 EPS (47c), consensus (26c)
|
Recommendations
|
Raymond James analyst… Raymond James analyst Andrew Cooper lowered the firm's price target on LumiraDx to $1.50 from $2 and keeps an Outperform rating on the shares. The company announced "yet another" restructuring program, this time aimed at an incremental $36M of annualized savings from a further 40% headcount reduction and other cost savings, the analyst tells investors in a research note. LumiraDx is paring down its focus, putting some projects on pause while focusing on those with the clearest opportunity to drive returns, says the firm. ShowHide Related Items >><< - 04/06/23
- LumiraDx to further reduce global workforce by 40%
- 02/27/23
- LumiraDx gets FDA EUA amendment for SARS-CoV-2 RNA STAR Complete test kit
- 02/06/23
- LumiraDx receives FDA EUA, U.K. CTDA approval for LumiraDx SARS-CoV-2 assay
- 01/31/23
- LumiraDx receives noncompliance notification from Nasdaq
- 12/19/22 Goldman Sachs
- LumiraDx initiated with a Neutral at Goldman Sachs
- 08/19/22 BTIG
- LumiraDx price target lowered to $4 from $7 at BTIG
- 05/12/22 Ladenburg
- LumiraDx price target lowered to $14 from $15.25 at Ladenburg
- 03/21/23
- LumiraDx reports Q4 adjusted EPS (12c), consensus (20c)
- 11/09/22
- LumiraDx reports Q3 EPS (47c), consensus (26c)
|
Hot Stocks
|
LumiraDx announced its… LumiraDx announced its Strategic Refocus and Cost Restructuring Program aimed at reducing its scale and operations to pre-pandemic levels and to further evolve LumiraDx into an agile organization with a clear focus on the areas with the greatest potential.The program is part of LumiraDx's ongoing efforts to streamline strategic focus and operations, optimize its cost structure and position itself for sustainable growth in the post-pandemic world. The restructuring will enable LumiraDx to focus its resources on key strategic priorities, including commercializing the existing product portfolio, expanding its product offerings in the United States through upcoming regulatory submissions and prioritizing the development and launch of its high sensitivity Troponin and Strep A Molecular tests. Under the Cost Restructuring Program, LumiraDx will further reduce its global workforce by approximately 40%, including full-time, part-time and contractor positions. The changes in workforce include adjusting to reduced Covid-related production volumes and focusing on streamlining operations in commercial and R&D activities while preserving core functions for revenue generation. In addition to the headcount reductions, LumiraDx will continue the implementation of operating cost reductions. The Cost Restructuring Program is expected to result in approximately $36 million in annualized savings, including the impact of the anticipated increased incremental costs to be incurred for US regulatory submissions, with the majority of savings realized within the next four months. ShowHide Related Items >><< - 02/27/23
- LumiraDx gets FDA EUA amendment for SARS-CoV-2 RNA STAR Complete test kit
- 02/06/23
- LumiraDx receives FDA EUA, U.K. CTDA approval for LumiraDx SARS-CoV-2 assay
- 01/31/23
- LumiraDx receives noncompliance notification from Nasdaq
- 11/14/22
- LumiraDx continues commercial expansion of HbA1c test
- 12/19/22 Goldman Sachs
- LumiraDx initiated with a Neutral at Goldman Sachs
- 08/19/22 BTIG
- LumiraDx price target lowered to $4 from $7 at BTIG
- 05/12/22 Ladenburg
- LumiraDx price target lowered to $14 from $15.25 at Ladenburg
- 03/21/23
- LumiraDx reports Q4 adjusted EPS (12c), consensus (20c)
- 11/09/22
- LumiraDx reports Q3 EPS (47c), consensus (26c)
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 03/21/23
- EU passenger car registrations up 11.5% in February
- 03/16/23
- Volkswagen unveils all-electric ID. 2all concept car
- 03/14/23
- Volkswagen: BEV deliveries rose 26% in 2022
- 03/14/23
- Volkswagen to invest EUR180B over 5 years in 'attractive' profit pools
USX U.S. Xpress Enterprises - 03/21/23
- U.S. Xpress Enterprises rises 300.7%
- 03/21/23
- U.S. Xpress Enterprises rises 294.3%
- 03/21/23
- U.S. Xpress Enterprises rises 294.7%
- 03/21/23
- US Xpress Enterprises trading resumes
- 03/14/23
- Tactile Systems appoints Birkemeyer as Chief Financial Officer
- 03/09/23
- UNH recommended by Indiana to serve Medicaid beneficiaries who are 60+
- 02/22/23
- UnitedHealth, Somatus expand kidney care agreement to five states
- 02/14/23
- Third Point buys AIG, exits T-Mobile in Q4
- 03/21/23
- Stevanato Group announces partnership with Thermo Fisher
- 03/15/23
- Thermo Fisher CEO sells $8.24M in common stock
- 02/22/23
- Thermo Fisher raises quarterly dividend 17% to 35c per share
- 02/14/23
- Lone Pine exited PayPal, initiated AMD position during Q4
- 03/21/23
- Tencent Music falls -10.0%
- 02/08/23
- Tencent Music announces integration of TME UNI Chart on Billboard's website
- 01/30/23
- Tencent Music falls -8.2%
- 01/30/23
- Tencent Music falls -10.0%
- 03/21/23
- Tilray announces Montauk Brewing expands distribution across Northeast
- 03/16/23
- Tilray holders approve charter amendment to 'support strategic growth'
- 03/16/23
- Tilray's SweetWater Brewing announces return of Triple Tail Tropical pale ale
- 03/07/23
- Tilray's SweetWater Brewing Company introduces Gone Trippin' IPA
SPY SPDR S&P 500 ETF Trust - 11/14/22
- Jana made new buy Freshpet top holding in Q3, also bought Momentive
- 03/01/23
- Einhorn says not invested long in artificial intelligence companies
- 03/01/23
- Einhorn says investors should be 'bearish on stocks and bullish on inflation'
- 12/14/22
- SEC proposes rules to enhance competition for retail order flow execution
- 11/07/22
- SEC Chief Prashant Yerramalli departing Dec. 31, Amanda Fischer to replace
- 03/16/23
- Astellas Pharma / Pfizer announce positive results from Embark trial of XTANDI
- 03/16/23
- Pfizer says continues to gather pediatric data on Paxlovid
- 03/16/23
- FDA advisory committee votes in support of safety and effectiveness of Paxlovid
- 03/16/23
- Pfizer recalls Nurtec ODT on packaging issues, risk of poisoning
- 03/20/23
- Pinduoduo falls 16% to $76.85 after reporting Q4 results
- 12/27/22
- China stocks rising with borders set to reopen on January 8
- 12/23/22
- PCAOB chair 'applauds' Congressional action to shorten HFCAA timeline
- 03/21/23
- On Holding rises 28.1%
- 03/21/23
- On Holding rises 24.1%
- 03/21/23
- On Holding rises 22.9%
- 03/21/23
- On Holding up 17% in pre-market trading at $25.21 after Q4 results and guidance
- 03/14/23
- Moderna announces two presentations on mRNA-4157/V940 at AACR
- 03/10/23
- Moderna expands U.S. presence, plans to hire 2,000 by end of 2023
- 02/23/23
- Moderna says $2.8B remaining under latest buyback authorization
- 02/23/23
- Moderna backs forecast of $5B in COVID-19 sales contracted for 2023 delivery
- 03/21/23
- Nvidia announces availability of new products featuring H100 Tensor Core GPU
- 03/15/23
- Facebook Ireland violated law over data use, Amsterdam court ruled
- 03/15/23
- Oportun Financial expands executive team with key new hires
- 03/14/23
- Meta targeting summer to complete analysis from hybrid work year of learning
- 02/27/23
- LumiraDx gets FDA EUA amendment for SARS-CoV-2 RNA STAR Complete test kit
- 02/06/23
- LumiraDx receives FDA EUA, U.K. CTDA approval for LumiraDx SARS-CoV-2 assay
- 01/31/23
- LumiraDx receives noncompliance notification from Nasdaq
- 11/14/22
- LumiraDx continues commercial expansion of HbA1c test
- 03/21/23
- Knight-Swift to acquire U.S. Xpress Enterprises for $6.15 per share
- 03/21/23
- Knight-Swift to acquire U.S. Xpress Enterprises for $6.15 per share
- 02/03/23
- Knight-Swift raises quarterly dividend to 14c from 12c per share
- 01/26/23
- Knight-Swift falls 3% to $56.00 after Q4 earnings miss
- 03/21/23
- Huya falls -15.1%
- 03/21/23
- Huya falls -12.5%
- 03/21/23
- Huya falls -8.4%
- 02/01/23
- Huya rises 12.2%
- 02/17/23
- Harley-Davidson raises quarterly dividend to 16.5c from 15.75c per share
- 02/15/23
- Sonic Automotive acquires Black Hills Harley-Davidson, terms not disclosed
- 02/02/23
- Harley-Davidson says 'comfortable' with inventory, demand signals
- 02/02/23
- Harley-Davidson 'remains optimistic on 2023 and beyond'
- 03/20/23
- Harmonic jumps 8% to $14.20 after technology partnership with Charter
- 03/20/23
- Harmonic, Charter announce partnership
- 02/16/23
- Harmonic CFO Sanjay Kalra to resign, Jeremy Rosenberg named interim CFO
- 03/21/23
- Nvidia says Google Cloud integrating newly launched L4 GPU, Vertex AI
- 03/17/23
- YouTube restores Donald Trump's channel
- 03/17/23
- Google ends enterprise sales of Google Glass
- 03/16/23
- YouTube TV raises monthly price to $72.99 from $64.99
- 03/01/23
- GoDaddy and Worldpay team to launch 'omnicommerce solution' Commerce 360
- 02/23/23
- GoDaddy announces launch of Payable Domains
- 02/14/23
- GoDaddy sees FY23 CapEx about $50M
- 02/14/23
- GoDaddy announces restructuring plan, reduction in force
- 03/21/23
- First Republic rises 34.2%
- 03/21/23
- First Republic trading resumes
- 03/21/23
- First Republic rises 25.7%
- 03/21/23
- First Republic trading halted, volatility trading pause
- 03/20/23
- Foot Locker focusing on banners, geographies that will drive growth, says CEO
- 03/20/23
- Foot Locker to close stores, ecommerce in Hong Kong, Macau
- 11/29/22
- Foot Locker announces leadership team appointments
- 11/18/22
- Foot Locker rises 14.7%
- 03/21/23
- Canadian Solar up 9% at $39.02 in pre-market after Q4 earnings beat
- 03/07/23
- Canadian Solar reports commercial operation of three solar projects in Japan
- 03/06/23
- Canadian Solar receives favorable EIA for 685 MW in Spain
- 02/27/23
- Canadian Solar renews EUR 100M note program
- 02/28/23
- Charter saw 'slight downtick' in rate of net adds in January vs. Q4
- 02/03/23
- Charter discloses legal settlements reached in January in annual filing
- 03/21/23
- Acreage obtains final order for strategic arrangement with Canopy Growth
- 03/16/23
- Acreage's floating shareholders approve approve arrangement with Canopy Growth
- 03/08/23
- Nano Dimension highlights 'serious allegations' against Murchinson
- 03/06/23
- Glass Lewis recommends Acreage shareholders vote for Canopy Growth arrangement
- 03/20/23
- BioNTech, OncoC4 enter collaboration to develop, commercialize ONC-392
- 03/01/23
- BioNTech announces establishment of interdisciplinary mRNA excellence center
- 01/13/23
- FDA sees preliminary safety signal for older users of Pfizer bivalent vaccine
- 01/10/23
- BioNTech enters agreement to acquire InstaDeep for GBP 362M in cash
- 03/21/23
- BlackBerry to sell non-core patents, applications to Malikie for $900M
- 03/07/23
- BlackBerry falls -13.3%
- 03/07/23
- BlackBerry falls -10.7%
- 02/13/23
- BlackBerry selected by Chongqing Yazaki to power digital LCD cluster in China
- 03/09/23
- Baxter treatment of short bowel syndrome granted FDA orphan designation
- 02/09/23
- Baxter falls -13.6%
- 02/09/23
- Baxter falls -10.1%
- 02/01/23
- Miromatrix Medical, Baxter enter research agreement for ALF
- 02/15/23
- Armstrong World appoints Monica Maheshwari as SVP, human resources
- 12/07/22
- Armstrong World Industries, Spacekit partner to offer acoustical wall art
- 10/19/22
- Armstrong World increases quarterly dividend 10% to 25.4c per share
- 03/21/23
- Altimmune falls 35% to $7.15 after initerim MOMENTUM Phase 2 trial data
- 03/21/23
- Altimmune announces reuslts from interim analysis of MOMENTUM Phase 2 trial
- 01/04/23
- Altimmune appoints Jordt as Chief Business Officer
- 12/20/22
- Altimmune announces topline results from 24-week trial of pemvidutide
- 03/21/23
- First Majestic falls -25.1%
- 03/21/23
- First Majestic falls -19.3%
- 03/21/23
- First Majestic falls -17.2%
- 03/20/23
- First Majestic falls 17% after announcing cost cuts, suspended mining activity
- 03/14/23
- Acreage Holdings releases impact analysis on New York cannabis market
- 03/21/23
- ProFrac Holding provides outlook for 2023
- 02/27/23
- ProFrac acquires Performance Proppants, upsizes ABL Credit Facility
- 12/27/22
- ProFrac Holding to acquire REV Energy, Performance Holdings
- 12/05/22
- ProFrac Holding to acquire Eagle Ford sand mining operations of Monarch Silica
- 03/20/23 Citi
- Citi sees 25 basis point hike from Fed on Wednesday
- 03/17/23 JPMorgan
- JPMorgan expects 25 point hike from Federal Reserve next week
- 03/07/23 JPMorgan
- JPMorgan says 'spooked' Powell opened door to 50 point hike
- 02/13/23 JPMorgan
- Stock market risk/reward 'skewed to the downside,' says JPMorgan
SPY SPDR S&P 500 ETF Trust - 03/21/23 TD Cowen
- Seagen price target raised to $229 from $145 at TD Cowen
- 03/20/23 Truist
- Seagen price target raised to $229 from $152 at Truist
- 03/17/23 Wells Fargo
- Pfizer price target lowered to $44 from $50 at Wells Fargo
- 03/15/23 Morgan Stanley
- Seagen downgraded to Equal Weight from Overweight at Morgan Stanley
- 12/15/22 BofA
- BioNTech upgraded to Buy at BofA oncology pipeline opportunities
- 12/15/22 BofA
- BioNTech upgraded to Buy from Neutral at BofA
- 11/08/22 Canaccord
- BioNTech price target lowered to $191 from $200 at Canaccord
- 10/24/22 JPMorgan
- BioNTech price target lowered to $132 from $183 at JPMorgan
- 03/13/23 TD Cowen
- Moderna upgraded to Outperform from Market Perform at TD Cowen
- 03/07/23 TD Cowen
- Moderna sees several disease growth opportunities, says TD Cowen
- 03/01/23 RBC Capital
- Moderna initiated with an Outperform at RBC Capital
- 02/28/23 Deutsche Bank
- Moderna price target lowered to $200 from $225 at Deutsche Bank
- 03/08/23 RBC Capital
- BlackBerry price target lowered to C$4.50 from C$5.50 at RBC Capital
- 12/21/22 Canaccord
- BlackBerry price target lowered to $4.50 from $5.00 at Canaccord
- 12/21/22 Baird
- BlackBerry price target lowered to $5 from $6 at Baird
- 09/28/22 TD Securities
- BlackBerry price target lowered to $4.75 from $5 at TD Securities
- 03/22/23 Wolfe Research
- Knight-Swift upgraded to Outperform on deal accretion at Wolfe Research
- 03/22/23 Wolfe Research
- Knight-Swift upgraded to Outperform from Peer Perform at Wolfe Research
- 03/21/23 BofA
- Knight-Swift price target raised to $76 from $70 at BofA
- 02/06/23 Barclays
- Knight-Swift price target raised to $72 from $62 at Barclays
USX U.S. Xpress Enterprises - 11/04/22 Wolfe Research
- U.S. Xpress upgraded to Peer Perform from Underperform at Wolfe Research
- 04/01/22 Stephens
- U.S. Xpress Enterprises price target lowered to $4.50 from $5 at Stephens
- 03/09/23 Citi
- Canadian Solar transferred at Neutral from Buy at Citi
- 03/09/23 Citi
- Canadian Solar downgraded to Neutral from Buy at Citi
- 02/09/23 Wells Fargo
- Canadian Solar price target raised to $46 from $33 at Wells Fargo
- 01/30/23 Goldman Sachs
- Canadian Solar price target raised to $36 from $33 at Goldman Sachs
- 03/22/23 KeyBanc
- Meta Platforms upgraded to Overweight from Sector Weight at KeyBanc
- 03/21/23 Morgan Stanley
- Meta Platforms upgraded to Overweight from Equal Weight at Morgan Stanley
- 03/20/23 Loop Capital
- Meta Platforms price target raised to $220 from $188 at Loop Capital
- 03/20/23 Edward Jones
- Meta Platforms upgraded to Buy from Hold at Edward Jones
- 03/21/23 Deutsche Bank
- Foot Locker price target raised to $42 from $36 at Deutsche Bank
- 03/21/23 Morgan Stanley
- Morgan Stanley 'skeptical' of 'show-me' story Foot Locker's long-term targets
- 03/21/23 Evercore ISI
- Foot Locker upgraded to Outperform from In Line at Evercore ISI
- 03/21/23 TD Cowen
- Foot Locker price target raised to $43 from $39 at TD Cowen
- 03/21/23 Morgan Stanley
- Harley-Davidson upgraded to Overweight from Equal Weight at Morgan Stanley
- 03/15/23 Jefferies
- Jefferies upgrades Harley-Davidson to Hold despite retail caution
- 03/15/23 Jefferies
- Harley-Davidson upgraded to Hold from Underperform at Jefferies
- 02/07/23 Morgan Stanley
- Harley-Davidson price target raised to $48 from $43 at Morgan Stanley
- 03/21/23 Piper Sandler
- GoDaddy downgraded to Neutral on shift to growth at Piper Sandler
- 03/21/23 Piper Sandler
- GoDaddy downgraded to Neutral from Overweight at Piper Sandler
- 02/15/23 Barclays
- GoDaddy price target lowered to $100 from $104 at Barclays
- 02/15/23 Raymond James
- GoDaddy price target raised to $94 from $88 at Raymond James
- 03/21/23 Deutsche Bank
- Deutsche downgrades Armstrong World on non-residential exposure
- 03/21/23 Deutsche Bank
- Armstrong World downgraded to Hold from Buy at Deutsche Bank
- 02/27/23 Deutsche Bank
- Armstrong World price target lowered to $91 from $99 at Deutsche Bank
- 02/22/23 Truist
- Armstrong World price target lowered to $90 from $95 at Truist
- 03/21/23 UBS
- Pinduoduo price target lowered to $100 from $110 at UBS
- 03/21/23 BofA
- Pinduoduo price target lowered to $95 from $108 at BofA
- 03/21/23 HSBC
- Pinduoduo price target lowered to $115 from $118 at HSBC
- 03/20/23 Citi
- Pinduoduo price target lowered to $115 from $127 at Citi
- 03/21/23 Morgan Stanley
- Microsoft app store longer-term Apple risk 'worth watching,' says Morgan Stanley
- 03/20/23 Stifel
- Alphabet resumed with a Buy at Stifel
- 03/17/23 Exane BNP Paribas
- Alphabet upgraded to Outperform from Neutral at Exane BNP Paribas
- 03/16/23 Macquarie
- Microsoft 'clear winner' in ongoing generative AI fight, says Macquarie
- 03/21/23 Morgan Stanley
- EV price cuts 'not a fad, but a trend,' says Morgan Stanley
- 03/07/23 Deutsche Bank
- Volkswagen price target raised to EUR 190 from EUR 180 at Deutsche Bank
- 03/03/23 HSBC
- Volkswagen downgraded to Hold from Buy at HSBC
- 01/30/23 Berenberg
- Volkswagen price target lowered to EUR 145 from EUR 160 at Berenberg
- 03/10/23 Chardan
- Gensight Biologics price target lowered to EUR 13 from EUR 15 at Chardan
- 02/06/23 Jefferies
- Jefferies says Catalent could be valued near $93 on average CDMO buyout multiple
- 02/02/23 Morgan Stanley
- Thermo Fisher price target raised to $670 from $613 at Morgan Stanley
- 02/02/23 TD Cowen
- Thermo Fisher price target raised to $711 from $690 at Cowen
- 02/13/23 Barclays
- Baxter price target lowered to $54 from $63 at Barclays
- 02/10/23 TD Cowen
- Baxter price target lowered to $45 from $70 at Cowen
- 02/06/23 KeyBanc
- Baxter price target lowered to $60 from $73 at KeyBanc
- 02/01/23 Piper Sandler
- Miromatrix MiroliverELAP timeline pushed out two or three quarters, says Piper
- 01/31/23 JPMorgan
- Medicare Advantage final rule more favorable than feared, says JPMorgan
- 01/24/23 Deutsche Bank
- UnitedHealth price target raised to $617 from $615 at Deutsche Bank
- 01/18/23 UBS
- UnitedHealth price target lowered to $550 from $590 at UBS
- 01/17/23 Loop Capital
- UnitedHealth price target raised to $590 from $575 at Loop Capital
- 03/21/23 Goldman Sachs
- First Republic rating suspended at Goldman Sachs
- 03/20/23 Evercore ISI
- Evercore ISI suspends rating on First Republic in light of uncertainty
- 03/20/23 Morgan Stanley
- Morgan Stanley removes First Republic price target amid 'wide range of outcomes'
- 03/17/23 Atlantic Equities
- First Republic downgraded to Neutral from Overweight at Atlantic Equities
- 03/21/23 Northland
- Harmonic price target raised to $23 from $20 at Northland
- 03/21/23 Jefferies
- Harmonic win worth $350M-plus over three years, says Jefferies
- 02/08/23 Jefferies
- Jefferies reveals top broadband plays, sees 5 years of strong growth
- 01/31/23 Barclays
- Harmonic price target raised to $20 from $17 at Barclays
- 02/21/23 Pivotal Research
- Liberty Broadband price target raised to $150 from $127 at Pivotal Research
- 02/09/23 Northland
- Emcore upgraded to Outperform at Northland on potential cable optics sale
- 01/10/23 MKM Partners
- Tilray price target lowered to $3 from $4 at MKM Partners
- 01/10/23 Canaccord
- Tilray price target lowered to $5 from $7 at Canaccord
- 01/09/23 Alliance Global Partners
- Tilray price target lowered to $3 from $4 at Alliance Global Partners
- 12/28/22 Piper Sandler
- Tilray estimates lowered on softer beer sales at Piper Sandler
- 02/13/23 Roth MKM
- Canopy Growth price target lowered to C$9 from C$11 at Roth MKM
- 02/10/23 Canaccord
- Canopy Growth price target lowered to C$3 from C$5 at Canaccord
- 02/10/23 CIBC
- Canopy Growth price target lowered to C$1.75 from C$2.50 at CIBC
- 02/10/23 Canaccord
- Canopy Growth price target lowered to C$3.00 from C$5.00 at Canaccord
- 10/26/22 Canaccord
- Acreage Holdings downgraded to Hold from Speculative Buy at Canaccord
- 10/26/22 Ladenburg
- Acreage Holdings downgraded to Neutral from Buy at Ladenburg
- 03/21/23 Goldman Sachs
- Altimmune downgraded to Neutral from Buy at Goldman Sachs
- 03/21/23 William Blair
- William Blair says Viking bull thesis intact after Altimmune data
- 03/21/23 H.C. Wainwright
- Altimmune attractive after 'overdone' selloff, says H.C. Wainwright
- 03/21/23 H.C. Wainwright
- Altimmune selloff on weight loss data overdone, says H.C. Wainwright
- 03/22/23 H.C. Wainwright
- First Majestic price target lowered to $10.50 from $12 at H.C. Wainwright
- 03/21/23 TD Securities
- First Majestic price target lowered to C$9 from C$11 at TD Securities
- 02/27/23 TD Securities
- First Majestic price target lowered to C$11 from C$12 at TD Securities
- 02/14/23 National Bank
- First Majestic price target lowered to C$11 from C$14.50 at National Bank
- 01/19/23 86 Research
- Tencent Music downgraded to Hold from Buy at 86 Research
- 12/01/22 Morgan Stanley
- Tencent Music upgraded at Morgan Stanley with sustainable growth ahead
- 12/01/22 Morgan Stanley
- Tencent Music upgraded to Overweight from Equal Weight at Morgan Stanley
- 11/22/22 JPMorgan
- Tencent Music upgraded to Overweight from Neutral at JPMorgan (yesterday)
- 03/22/23 HSBC
- Huya price target lowered to $3.80 from $6.30 at HSBC
- 02/02/23 HSBC
- Huya price target raised to $6.30 from $4.60 at HSBC
- 12/13/22 China Renaissance
- China Renaissance upgrades Huya on end of regulation tightening
- 12/13/22 China Renaissance
- Huya upgraded to Buy from Hold at China Renaissance
- 03/21/23 UBS
- On Holding Q4 results were 'exceptional', says UBS
- 03/21/23 Credit Suisse
- On Holding price target raised to $33 from $28 at Credit Suisse
- 03/21/23 Morgan Stanley
- On Holding price target raised to $33 from $26 at Morgan Stanley
- 03/21/23 Stifel
- On Holding price target raised to $35 from $31 at Stifel
- 12/19/22 Goldman Sachs
- LumiraDx initiated with a Neutral at Goldman Sachs
- 08/19/22 BTIG
- LumiraDx price target lowered to $4 from $7 at BTIG
- 05/12/22 Ladenburg
- LumiraDx price target lowered to $14 from $15.25 at Ladenburg
- 01/12/23 JPMorgan
- ProFrac Holding price target raised to $32 from $30 at JPMorgan
- 01/10/23 Piper Sandler
- ProFrac Holding price target raised to $35 from $31.50 at Piper Sandler
- 12/28/22 Stifel
- ProFrac Holding addition of new assets a positive, says Stifel
- 11/14/22 Stifel
- ProFrac Holding price target raised to $38 from $29 at Stifel
- 03/03/23
- Volkswagen reports FY22 revenue EUR279.2B, up 11.6%
- 02/07/23
- Volkswagen reports preliminary FY adjusted operating profit EUR 22.5B
- 10/28/22
- Volkswagen reports Q3 revenue EUR 70.7B vs. EUR 56.9B last year
USX U.S. Xpress Enterprises - 02/09/23
- U.S. Xpress Enterprises reports Q4 adjusted EPS (18c), consensus (13c)
- 11/03/22
- U.S. Xpress Enterprises reports Q3 EPS (38c), consensus (9c)
- 01/13/23
- UnitedHealth backs FY23 adjusted EPS view $24.40-$24.90, consensus $24.94
- 01/13/23
- UnitedHealth reports Q4 adjusted EPS $5.34, consensus $5.17
- 01/12/23
- Notable companies reporting before tomorrow's open
- 02/01/23
- Thermo Fisher sees Q1 EPS over 20% of full-year total, consensus $5.41
- 02/01/23
- Thermo Fisher sees FY23 adjusted EPS $23.70, consensus $23.21
- 02/01/23
- Thermo Fisher reports Q4 adjusted EPS $5.40, consensus $5.19
- 01/31/23
- Notable companies reporting before tomorrow's open
- 03/21/23
- Tencent Music reports Q4 EPS 11c, consensus 13c
- 11/15/22
- Tencent Music reports Q3 EPS 12c, consensus 10c
- 01/09/23
- Tilray reports Q2 adjusted EPS (6c) vs. (8c) last year
- 10/07/22
- Tilray reports Q1 adjusted EPS (8c) vs. (13c) last year
- 03/15/23
- Royalty Pharma raises FY23 adjusted cash receipt guidance to $2.85B-$2.95B
- 01/31/23
- Pfizer sees FY23 adjusted EPS $3.25-$3.45, consensus $4.44
- 01/31/23
- Pfizer reports Q4 adjusted EPS $1.14, consensus $1.05
- 01/30/23
- Notable companies reporting before tomorrow's open
- 03/20/23
- Pinduoduo reports Q4 adjusted EPS $1.21, consensus $1.21
- 11/28/22
- Pinduoduo reports Q3 adjusted EPS $1.21, consensus 65c
- 03/21/23
- On Holding sees FY23 revenue of 'at least' CHF 1.7B vs. CHF 1.22B last year
- 03/21/23
- On Holding reports Q4 EPS CHF0.02 vs. (CHF0.04) last year
- 11/16/22
- On Holding raises FY22 revenue view to CHF 1.125B from CHF 1.1B
- 11/16/22
- On Holding reports Q3 EPS CHF0.06 vs. CHF0.04 last year
- 02/23/23
- Moderna reports Q4 EPS $3.61, consensus $4.67
- 02/22/23
- Notable companies reporting before tomorrow's open
- 11/03/22
- Moderna reports Q3 EPS $2.53, consensus $3.29
- 02/01/23
- Meta Platforms sees Q1 revenue $26B-$28.5B, consensus $27.14B
- 02/01/23
- Meta Platforms reports Q4 EPS $1.76, consensus $2.22
- 02/01/23
- Notable companies reporting after market close
- 11/09/22
- Meta Platforms backs Q4 revenue outlook $30B-$32.5B, consensus $31.52B
- 03/21/23
- LumiraDx reports Q4 adjusted EPS (12c), consensus (20c)
- 11/09/22
- LumiraDx reports Q3 EPS (47c), consensus (26c)
- 01/26/23
- Knight-Swift sees FY23 EPS $4.05-$4.25, consensus $4.16
- 01/26/23
- Knight-Swift reports Q4 EPS $1.00, consensus $1.12
- 10/19/22
- Knight-Swift cuts FY22 EPS view to $5.17-$5.22 from $5.30-$5.45 prior
- 10/19/22
- Knight-Swift reports Q3 adjusted EPS $1.27, consensus $1.32
- 03/21/23
- Huya reports Q4 EPS (26c), consensus (30c)
- 11/15/22
- Huya reports Q3 EPS 6c, consensus (3c)
- 02/02/23
- Harley-Davidson reports Q4 EPS 28c, consensus 6c
- 10/26/22
- Harley-Davidson reaffirms FY22 revenue view increase 5%-10%
- 10/26/22
- Harley-Davidson reports Q3 GAAP EPS $1.78, consensus $1.40
- 10/25/22
- Notable companies reporting before tomorrow's open
- 01/30/23
- Harmonic sees FY23 non-GAAP EPS 56c-72c, consensus 74c
- 01/30/23
- Harmonic sees Q1 non-GAAP EPS 7c-10c, consensus 10c
- 01/30/23
- Harmonic reports Q4 non-GAAP EPS 17c, consensus 14c
- 10/31/22
- Harmonic reports Q3 non-GAAP EPS 13c, consensus 10c
- 02/02/23
- Alphabet reports Q4 EPS $1.05, consensus $1.18
- 02/02/23
- Notable companies reporting after market close
- 10/25/22
- Alphabet reports Q3 EPS $1.06, consensus $1.25
- 10/25/22
- Notable companies reporting after market close
- 02/14/23
- GoDaddy sees FY23 revenue $4.25B-$4.325B, consensus $4.35B
- 02/14/23
- GoDaddy sees Q1 revenue $1.03B-$1.05B, consensus $1.05B
- 02/14/23
- GoDaddy reports Q4 EPS 60c, consensus 62c
- 02/14/23
- Notable companies reporting after market close
- 01/13/23
- First Republic reports Q4 EPS $1.88, consensus $1.80
- 10/14/22
- First Republic reports Q3 EPS $2.21, consensus $2.18
- 03/20/23
- Foot Locker targeting adjusted EPS growth in low to mid 20% range for FY24-FY26
- 03/20/23
- Foot Locker sees FY23 adjusted EPS $3.35-$3.65, consensus $4.48
- 03/20/23
- Foot Locker reports Q4 adjusted EPS 97c, consensus 51c
- 11/18/22
- Foot Locker raises FY22 EPS view to $4.42-$4.50 from $4.25-$4.45
- 03/21/23
- Canadian Solar sees FY23 revenue $8.5B-$9.5B, consensus $9.88B
- 03/21/23
- Canadian Solar sees Q1 revenue $1.6B-$1.8B, consensus $1.95B
- 03/21/23
- Canadian Solar reports Q4 EPS $1.11, consensus 76c
- 02/24/23
- Canadian Solar sees Q1 revenue $1.6B_$1.8B, consensus $2.04B
- 01/27/23
- Charter reports Q4 EPS $7.69, consensus $8.79
- 01/26/23
- Notable companies reporting before tomorrow's open
- 10/28/22
- Charter reports Q3 EPS $7.38, consensus $8.23
- 02/09/23
- Canopy Growth reports Q3 EPS (C$0.54) vs. (C$0.28) a year ago
- 11/09/22
- Canopy Growth reports Q2 adjusted EBITDA (C$78.1M), up 52% y/y
- 10/06/22
- Constellation Brands reports Q2 comparable EPS ex-Canopy losses $3.33
- 11/07/22
- BioNTech reports Q3 EPS EUR 6.98 vs. EUR 12.35 last year
- 03/07/23
- BlackBerry sees FY23 revenue $656M, consensus $674.73M
- 03/07/23
- BlackBerry reports preliminary Q4 revenue $151M, consensus $168.45M
- 12/20/22
- BlackBerry reports Q3 adjusted EPS (5c), consensus (7c)
- 09/27/22
- BlackBerry reports Q2 EPS (5c), consensus (7c)
- 02/09/23
- Baxter sees FY23 adjusted EPS $2.75-$2,95, consensus $3.56
- 02/09/23
- Baxter sees Q1 adjusted EPS 46c-50c, consensus 76c
- 02/09/23
- Baxter reports Q4 adjusted EPS 88c, consensus 94c
- 02/08/23
- Notable companies reporting before tomorrow's open
- 02/21/23
- Armstrong World sees FY23 adjusted EPS $4.80-$5.05, consensus $5.25
- 02/21/23
- Armstrong World reports Q4 adjusted EPS $1.08, consensus $1.12
- 10/25/22
- Armstrong World lowers 2022 adjusted EPS view to $4.75-$4.85 from $5.10-$5.20
- 10/25/22
- Armstrong World reports Q3 adjusted EPS $1.36, consensus $1.47
- 02/28/23
- Altimmune reports Q4 EPS (43c), consensus (50c)
- 11/10/22
- Altimmune reports Q3 EPS (48c), consensus (50c)
- 03/21/23
- ProFrac Holding reports Q4 EPS 82c, consensus 88c
- 11/10/22
- ProFrac Holding sees Q4 revenue above Q3, consensus $755.54M
- 11/10/22
- ProFrac Holding reports Q3 EPS $1.09, consensus 86c
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 03/21/23
- EU passenger car registrations up 11.5% in February
- 03/16/23
- Volkswagen unveils all-electric ID. 2all concept car
- 03/14/23
- Volkswagen: BEV deliveries rose 26% in 2022
- 03/14/23
- Volkswagen to invest EUR180B over 5 years in 'attractive' profit pools
USX U.S. Xpress Enterprises - 03/21/23
- U.S. Xpress Enterprises rises 300.7%
- 03/21/23
- U.S. Xpress Enterprises rises 294.3%
- 03/21/23
- U.S. Xpress Enterprises rises 294.7%
- 03/21/23
- US Xpress Enterprises trading resumes
- 03/21/23
- Nvidia says software library for computational lithography integrated by TSMC
- 02/14/23
- Berkshire added more of top-holding Apple, Paramount in Q4
- 02/14/23
- Lone Pine exited PayPal, initiated AMD position during Q4
- 01/24/23
- Taiwan Semi trading resumes
- 03/21/23
- Stevanato Group announces partnership with Thermo Fisher
- 03/15/23
- Thermo Fisher CEO sells $8.24M in common stock
- 02/22/23
- Thermo Fisher raises quarterly dividend 17% to 35c per share
- 03/21/23
- Tencent Music falls -10.0%
- 02/08/23
- Tencent Music announces integration of TME UNI Chart on Billboard's website
- 01/30/23
- Tencent Music falls -8.2%
- 01/30/23
- Tencent Music falls -10.0%
- 03/21/23
- Tilray announces Montauk Brewing expands distribution across Northeast
- 03/16/23
- Tilray holders approve charter amendment to 'support strategic growth'
- 03/16/23
- Tilray's SweetWater Brewing announces return of Triple Tail Tropical pale ale
- 03/07/23
- Tilray's SweetWater Brewing Company introduces Gone Trippin' IPA
- 03/01/23
- Einhorn says not invested long in artificial intelligence companies
- 03/01/23
- Einhorn says investors should be 'bearish on stocks and bullish on inflation'
- 12/14/22
- SEC proposes rules to enhance competition for retail order flow execution
- 11/07/22
- SEC Chief Prashant Yerramalli departing Dec. 31, Amanda Fischer to replace
- 03/16/23
- Astellas Pharma / Pfizer announce positive results from Embark trial of XTANDI
- 03/16/23
- Pfizer says continues to gather pediatric data on Paxlovid
- 03/16/23
- FDA advisory committee votes in support of safety and effectiveness of Paxlovid
- 03/16/23
- Pfizer recalls Nurtec ODT on packaging issues, risk of poisoning
- 03/20/23
- Pinduoduo falls 16% to $76.85 after reporting Q4 results
- 12/27/22
- China stocks rising with borders set to reopen on January 8
- 12/23/22
- PCAOB chair 'applauds' Congressional action to shorten HFCAA timeline
- 03/21/23
- On Holding rises 28.1%
- 03/21/23
- On Holding rises 24.1%
- 03/21/23
- On Holding rises 22.9%
- 03/21/23
- On Holding up 17% in pre-market trading at $25.21 after Q4 results and guidance
- 03/21/23
- Nvidia, Adobe to co-develop new generation of advanced generative AI models
- 03/21/23
- Nvidia unveils language models, generative AI service to help Life Sciences R&D
- 03/21/23
- Nvidia announces new 'AI Foundations' services
- 03/14/23
- Moderna announces two presentations on mRNA-4157/V940 at AACR
- 03/10/23
- Moderna expands U.S. presence, plans to hire 2,000 by end of 2023
- 02/23/23
- Moderna says $2.8B remaining under latest buyback authorization
- 02/23/23
- Moderna backs forecast of $5B in COVID-19 sales contracted for 2023 delivery
- 03/21/23
- Nvidia announces availability of new products featuring H100 Tensor Core GPU
- 03/15/23
- Facebook Ireland violated law over data use, Amsterdam court ruled
- 03/15/23
- Oportun Financial expands executive team with key new hires
- 03/14/23
- Meta targeting summer to complete analysis from hybrid work year of learning
- 02/27/23
- LumiraDx gets FDA EUA amendment for SARS-CoV-2 RNA STAR Complete test kit
- 02/06/23
- LumiraDx receives FDA EUA, U.K. CTDA approval for LumiraDx SARS-CoV-2 assay
- 01/31/23
- LumiraDx receives noncompliance notification from Nasdaq
- 11/14/22
- LumiraDx continues commercial expansion of HbA1c test
- 03/21/23
- Knight-Swift to acquire U.S. Xpress Enterprises for $6.15 per share
- 03/21/23
- Knight-Swift to acquire U.S. Xpress Enterprises for $6.15 per share
- 02/03/23
- Knight-Swift raises quarterly dividend to 14c from 12c per share
- 01/26/23
- Knight-Swift falls 3% to $56.00 after Q4 earnings miss
- 03/21/23
- Huya falls -15.1%
- 03/21/23
- Huya falls -12.5%
- 03/21/23
- Huya falls -8.4%
- 02/01/23
- Huya rises 12.2%
- 02/17/23
- Harley-Davidson raises quarterly dividend to 16.5c from 15.75c per share
- 02/15/23
- Sonic Automotive acquires Black Hills Harley-Davidson, terms not disclosed
- 02/02/23
- Harley-Davidson says 'comfortable' with inventory, demand signals
- 02/02/23
- Harley-Davidson 'remains optimistic on 2023 and beyond'
- 03/20/23
- Harmonic jumps 8% to $14.20 after technology partnership with Charter
- 03/20/23
- Harmonic, Charter announce partnership
- 02/16/23
- Harmonic CFO Sanjay Kalra to resign, Jeremy Rosenberg named interim CFO
- 03/17/23
- YouTube restores Donald Trump's channel
- 03/17/23
- Google ends enterprise sales of Google Glass
- 03/16/23
- YouTube TV raises monthly price to $72.99 from $64.99
- 03/15/23
- Microsoft's Mojang says 'Minecraft' launching on Chromebook
- 03/01/23
- GoDaddy and Worldpay team to launch 'omnicommerce solution' Commerce 360
- 02/23/23
- GoDaddy announces launch of Payable Domains
- 02/14/23
- GoDaddy sees FY23 CapEx about $50M
- 02/14/23
- GoDaddy announces restructuring plan, reduction in force
- 03/20/23
- Foot Locker focusing on banners, geographies that will drive growth, says CEO
- 03/20/23
- Foot Locker to close stores, ecommerce in Hong Kong, Macau
- 11/29/22
- Foot Locker announces leadership team appointments
- 11/18/22
- Foot Locker rises 14.7%
- 03/21/23
- Canadian Solar up 9% at $39.02 in pre-market after Q4 earnings beat
- 03/07/23
- Canadian Solar reports commercial operation of three solar projects in Japan
- 03/06/23
- Canadian Solar receives favorable EIA for 685 MW in Spain
- 02/27/23
- Canadian Solar renews EUR 100M note program
- 03/21/23
- Chubb says does not have exposure to any Credit Suisse AT1 bonds
- 03/20/23
- S&P revises UBS Group outlook to Negative, affirms ratings
- 03/19/23
- Fly Intel: Top five weekend stock stories
- 03/19/23
- Credit Suisse says UBS confident staff employment will be continued
- 03/21/23
- Acreage obtains final order for strategic arrangement with Canopy Growth
- 03/16/23
- Acreage's floating shareholders approve approve arrangement with Canopy Growth
- 03/08/23
- Nano Dimension highlights 'serious allegations' against Murchinson
- 03/06/23
- Glass Lewis recommends Acreage shareholders vote for Canopy Growth arrangement
- 03/20/23
- BioNTech, OncoC4 enter collaboration to develop, commercialize ONC-392
- 03/01/23
- BioNTech announces establishment of interdisciplinary mRNA excellence center
- 01/13/23
- FDA sees preliminary safety signal for older users of Pfizer bivalent vaccine
- 01/10/23
- BioNTech enters agreement to acquire InstaDeep for GBP 362M in cash
- 03/21/23
- BlackBerry to sell non-core patents, applications to Malikie for $900M
- 03/07/23
- BlackBerry falls -13.3%
- 03/07/23
- BlackBerry falls -10.7%
- 02/13/23
- BlackBerry selected by Chongqing Yazaki to power digital LCD cluster in China
- 03/09/23
- Baxter treatment of short bowel syndrome granted FDA orphan designation
- 02/09/23
- Baxter falls -13.6%
- 02/09/23
- Baxter falls -10.1%
- 02/01/23
- Miromatrix Medical, Baxter enter research agreement for ALF
- 02/15/23
- Armstrong World appoints Monica Maheshwari as SVP, human resources
- 12/07/22
- Armstrong World Industries, Spacekit partner to offer acoustical wall art
- 10/19/22
- Armstrong World increases quarterly dividend 10% to 25.4c per share
- 03/21/23
- Altimmune falls 35% to $7.15 after initerim MOMENTUM Phase 2 trial data
- 03/21/23
- Altimmune announces reuslts from interim analysis of MOMENTUM Phase 2 trial
- 01/04/23
- Altimmune appoints Jordt as Chief Business Officer
- 12/20/22
- Altimmune announces topline results from 24-week trial of pemvidutide
- 03/21/23
- First Majestic falls -25.1%
- 03/21/23
- First Majestic falls -19.3%
- 03/21/23
- First Majestic falls -17.2%
- 03/20/23
- First Majestic falls 17% after announcing cost cuts, suspended mining activity
- 03/14/23
- Acreage Holdings releases impact analysis on New York cannabis market
- 03/21/23
- ProFrac Holding provides outlook for 2023
- 02/27/23
- ProFrac acquires Performance Proppants, upsizes ABL Credit Facility
- 12/27/22
- ProFrac Holding to acquire REV Energy, Performance Holdings
- 12/05/22
- ProFrac Holding to acquire Eagle Ford sand mining operations of Monarch Silica
- 03/20/23 Citi
- Citi sees 25 basis point hike from Fed on Wednesday
- 03/17/23 JPMorgan
- JPMorgan expects 25 point hike from Federal Reserve next week
- 03/07/23 JPMorgan
- JPMorgan says 'spooked' Powell opened door to 50 point hike
- 02/13/23 JPMorgan
- Stock market risk/reward 'skewed to the downside,' says JPMorgan
- 03/21/23 TD Cowen
- Seagen price target raised to $229 from $145 at TD Cowen
- 03/20/23 Truist
- Seagen price target raised to $229 from $152 at Truist
- 03/17/23 Wells Fargo
- Pfizer price target lowered to $44 from $50 at Wells Fargo
- 03/15/23 Morgan Stanley
- Seagen downgraded to Equal Weight from Overweight at Morgan Stanley
- 12/15/22 BofA
- BioNTech upgraded to Buy at BofA oncology pipeline opportunities
- 12/15/22 BofA
- BioNTech upgraded to Buy from Neutral at BofA
- 11/08/22 Canaccord
- BioNTech price target lowered to $191 from $200 at Canaccord
- 10/24/22 JPMorgan
- BioNTech price target lowered to $132 from $183 at JPMorgan
- 03/13/23 TD Cowen
- Moderna upgraded to Outperform from Market Perform at TD Cowen
- 03/07/23 TD Cowen
- Moderna sees several disease growth opportunities, says TD Cowen
- 03/01/23 RBC Capital
- Moderna initiated with an Outperform at RBC Capital
- 02/28/23 Deutsche Bank
- Moderna price target lowered to $200 from $225 at Deutsche Bank
- 03/08/23 RBC Capital
- BlackBerry price target lowered to C$4.50 from C$5.50 at RBC Capital
- 12/21/22 Canaccord
- BlackBerry price target lowered to $4.50 from $5.00 at Canaccord
- 12/21/22 Baird
- BlackBerry price target lowered to $5 from $6 at Baird
- 09/28/22 TD Securities
- BlackBerry price target lowered to $4.75 from $5 at TD Securities
- 02/06/23 Barclays
- Knight-Swift price target raised to $72 from $62 at Barclays
- 02/02/23 BofA
- Interactive Brokers, Knight-Swift, PG&E added to 'US 1' list at BofA
- 01/27/23 Stephens
- Knight-Swift price target raised to $75 from $65 at Stephens
- 01/27/23 KeyBanc
- Knight-Swift price target raised to $67 from $60 at KeyBanc
USX U.S. Xpress Enterprises - 11/04/22 Wolfe Research
- U.S. Xpress upgraded to Peer Perform from Underperform at Wolfe Research
- 04/01/22 Stephens
- U.S. Xpress Enterprises price target lowered to $4.50 from $5 at Stephens
- 03/09/23 Citi
- Canadian Solar transferred at Neutral from Buy at Citi
- 03/09/23 Citi
- Canadian Solar downgraded to Neutral from Buy at Citi
- 02/09/23 Wells Fargo
- Canadian Solar price target raised to $46 from $33 at Wells Fargo
- 01/30/23 Goldman Sachs
- Canadian Solar price target raised to $36 from $33 at Goldman Sachs
- 03/21/23 Morgan Stanley
- Meta Platforms upgraded to Overweight from Equal Weight at Morgan Stanley
- 03/20/23 Loop Capital
- Meta Platforms price target raised to $220 from $188 at Loop Capital
- 03/20/23 Edward Jones
- Meta Platforms upgraded to Buy from Hold at Edward Jones
- 03/17/23 TD Cowen
- Meta Platforms price target raised to $190 from $175 at TD Cowen
- 03/21/23 Deutsche Bank
- Foot Locker price target raised to $42 from $36 at Deutsche Bank
- 03/21/23 Morgan Stanley
- Morgan Stanley 'skeptical' of 'show-me' story Foot Locker's long-term targets
- 03/21/23 Evercore ISI
- Foot Locker upgraded to Outperform from In Line at Evercore ISI
- 03/21/23 TD Cowen
- Foot Locker price target raised to $43 from $39 at TD Cowen
- 03/21/23 Morgan Stanley
- Harley-Davidson upgraded to Overweight from Equal Weight at Morgan Stanley
- 03/15/23 Jefferies
- Jefferies upgrades Harley-Davidson to Hold despite retail caution
- 03/15/23 Jefferies
- Harley-Davidson upgraded to Hold from Underperform at Jefferies
- 02/07/23 Morgan Stanley
- Harley-Davidson price target raised to $48 from $43 at Morgan Stanley
- 03/21/23 Piper Sandler
- GoDaddy downgraded to Neutral on shift to growth at Piper Sandler
- 03/21/23 Piper Sandler
- GoDaddy downgraded to Neutral from Overweight at Piper Sandler
- 02/15/23 Barclays
- GoDaddy price target lowered to $100 from $104 at Barclays
- 02/15/23 Raymond James
- GoDaddy price target raised to $94 from $88 at Raymond James
- 03/21/23 Deutsche Bank
- Deutsche downgrades Armstrong World on non-residential exposure
- 03/21/23 Deutsche Bank
- Armstrong World downgraded to Hold from Buy at Deutsche Bank
- 02/27/23 Deutsche Bank
- Armstrong World price target lowered to $91 from $99 at Deutsche Bank
- 02/22/23 Truist
- Armstrong World price target lowered to $90 from $95 at Truist
- 03/20/23 Barclays
- European Banks sector view downgraded to Neutral at Barclays
- 03/20/23 Societe Generale
- UBS downgraded to Hold from Buy at Societe Generale
- 03/20/23 BofA
- UBS upgraded to Buy from Neutral at BofA
- 03/16/23 JPMorgan
- Credit Suisse gets short-term relief, but questions remain, says JPMorgan
- 01/27/23 BofA
- Intel price target lowered to $25 from $28 at BofA
- 01/12/23 Needham
- Impinj price target raised to $130 from $120 at Needham
- 01/10/23 Morgan Stanley
- TSMC named a 'Catalyst Driven Idea' at Morgan Stanley
- 11/18/22 Erste Group
- TSMC upgraded to Buy from Hold at Erste Group
- 03/21/23 Exane BNP Paribas
- Nvidia upgraded to Neutral from Underperform at Exane BNP Paribas
- 03/20/23 Baird
- Nvidia price target raised to $300 from $230 at Baird
- 03/20/23 BofA
- Nvidia's GTC to reinforce AI leadership, says BofA
- 03/17/23 Citi
- Nvidia price target raised to $305 from $245 at Citi
- 03/21/23 Morgan Stanley
- EV price cuts 'not a fad, but a trend,' says Morgan Stanley
- 03/07/23 Deutsche Bank
- Volkswagen price target raised to EUR 190 from EUR 180 at Deutsche Bank
- 03/03/23 HSBC
- Volkswagen downgraded to Hold from Buy at HSBC
- 01/30/23 Berenberg
- Volkswagen price target lowered to EUR 145 from EUR 160 at Berenberg
- 03/10/23 Chardan
- Gensight Biologics price target lowered to EUR 13 from EUR 15 at Chardan
- 02/06/23 Jefferies
- Jefferies says Catalent could be valued near $93 on average CDMO buyout multiple
- 02/02/23 Morgan Stanley
- Thermo Fisher price target raised to $670 from $613 at Morgan Stanley
- 02/02/23 TD Cowen
- Thermo Fisher price target raised to $711 from $690 at Cowen
- 02/13/23 Barclays
- Baxter price target lowered to $54 from $63 at Barclays
- 02/10/23 TD Cowen
- Baxter price target lowered to $45 from $70 at Cowen
- 02/06/23 KeyBanc
- Baxter price target lowered to $60 from $73 at KeyBanc
- 02/01/23 Piper Sandler
- Miromatrix MiroliverELAP timeline pushed out two or three quarters, says Piper
- 03/21/23 Northland
- Harmonic price target raised to $23 from $20 at Northland
- 03/21/23 Jefferies
- Harmonic win worth $350M-plus over three years, says Jefferies
- 02/08/23 Jefferies
- Jefferies reveals top broadband plays, sees 5 years of strong growth
- 01/31/23 Barclays
- Harmonic price target raised to $20 from $17 at Barclays
- 01/10/23 MKM Partners
- Tilray price target lowered to $3 from $4 at MKM Partners
- 01/10/23 Canaccord
- Tilray price target lowered to $5 from $7 at Canaccord
- 01/09/23 Alliance Global Partners
- Tilray price target lowered to $3 from $4 at Alliance Global Partners
- 12/28/22 Piper Sandler
- Tilray estimates lowered on softer beer sales at Piper Sandler
- 02/13/23 Roth MKM
- Canopy Growth price target lowered to C$9 from C$11 at Roth MKM
- 02/10/23 Canaccord
- Canopy Growth price target lowered to C$3 from C$5 at Canaccord
- 02/10/23 CIBC
- Canopy Growth price target lowered to C$1.75 from C$2.50 at CIBC
- 02/10/23 Canaccord
- Canopy Growth price target lowered to C$3.00 from C$5.00 at Canaccord
- 10/26/22 Canaccord
- Acreage Holdings downgraded to Hold from Speculative Buy at Canaccord
- 10/26/22 Ladenburg
- Acreage Holdings downgraded to Neutral from Buy at Ladenburg
- 03/21/23 H.C. Wainwright
- Altimmune attractive after 'overdone' selloff, says H.C. Wainwright
- 03/21/23 H.C. Wainwright
- Altimmune selloff on weight loss data overdone, says H.C. Wainwright
- 03/21/23 JMP Securities
- Altimmune's Pemvi 'at least as good' as semaglutide, says JMP Securities
- 02/28/23 B. Riley
- B. Riley keeps Buy rating on Altimmune after Q4 results, pipeline updates
- 03/21/23 TD Securities
- First Majestic price target lowered to C$9 from C$11 at TD Securities
- 02/27/23 TD Securities
- First Majestic price target lowered to C$11 from C$12 at TD Securities
- 02/14/23 National Bank
- First Majestic price target lowered to C$11 from C$14.50 at National Bank
- 01/20/23 BMO Capital
- First Majestic price target lowered to C$9 from C$10.50 at BMO Capital
- 01/19/23 86 Research
- Tencent Music downgraded to Hold from Buy at 86 Research
- 12/01/22 Morgan Stanley
- Tencent Music upgraded at Morgan Stanley with sustainable growth ahead
- 12/01/22 Morgan Stanley
- Tencent Music upgraded to Overweight from Equal Weight at Morgan Stanley
- 11/22/22 JPMorgan
- Tencent Music upgraded to Overweight from Neutral at JPMorgan (yesterday)
- 02/02/23 HSBC
- Huya price target raised to $6.30 from $4.60 at HSBC
- 12/13/22 China Renaissance
- China Renaissance upgrades Huya on end of regulation tightening
- 12/13/22 China Renaissance
- Huya upgraded to Buy from Hold at China Renaissance
- 11/16/22 Citi
- Huya downgraded to Sell at Citi on slower industry outlook
- 03/16/23 Wedbush
- Wedbush upgrades On Holding to Outperform, raises price target to $25
- 03/16/23 Wedbush
- On Holding upgraded to Outperform from Neutral at Wedbush
- 03/13/23 UBS
- On Holding price target raised to $27 from $25 at UBS
- 01/04/23 Piper Sandler
- Wolverine World Wide downgraded to Neutral from Overweight at Piper Sandler
- 12/19/22 Goldman Sachs
- LumiraDx initiated with a Neutral at Goldman Sachs
- 08/19/22 BTIG
- LumiraDx price target lowered to $4 from $7 at BTIG
- 05/12/22 Ladenburg
- LumiraDx price target lowered to $14 from $15.25 at Ladenburg
- 01/12/23 JPMorgan
- ProFrac Holding price target raised to $32 from $30 at JPMorgan
- 01/10/23 Piper Sandler
- ProFrac Holding price target raised to $35 from $31.50 at Piper Sandler
- 12/28/22 Stifel
- ProFrac Holding addition of new assets a positive, says Stifel
- 11/14/22 Stifel
- ProFrac Holding price target raised to $38 from $29 at Stifel
- 03/21/23 UBS
- Pinduoduo price target lowered to $100 from $110 at UBS
- 03/21/23 BofA
- Pinduoduo price target lowered to $95 from $108 at BofA
- 03/21/23 HSBC
- Pinduoduo price target lowered to $115 from $118 at HSBC
- 03/20/23 Citi
- Pinduoduo price target lowered to $115 from $127 at Citi
- 03/21/23 Morgan Stanley
- Microsoft app store longer-term Apple risk 'worth watching,' says Morgan Stanley
- 03/20/23 Stifel
- Alphabet resumed with a Buy at Stifel
- 03/17/23 Exane BNP Paribas
- Alphabet upgraded to Outperform from Neutral at Exane BNP Paribas
- 03/16/23 Macquarie
- Microsoft 'clear winner' in ongoing generative AI fight, says Macquarie
- 03/03/23
- Volkswagen reports FY22 revenue EUR279.2B, up 11.6%
- 02/07/23
- Volkswagen reports preliminary FY adjusted operating profit EUR 22.5B
- 10/28/22
- Volkswagen reports Q3 revenue EUR 70.7B vs. EUR 56.9B last year
USX U.S. Xpress Enterprises - 02/09/23
- U.S. Xpress Enterprises reports Q4 adjusted EPS (18c), consensus (13c)
- 11/03/22
- U.S. Xpress Enterprises reports Q3 EPS (38c), consensus (9c)
- 01/12/23
- TSMC sees Q1 revenue $16.7B-$17.5B, consensus $17.71B
- 01/12/23
- TSMC reports Q4 EPS $1.82, consensus $1.77
- 10/13/22
- TSMC sees Q4 revenue $19.9B-$20.7B, consensus $19.76B
- 10/13/22
- TSMC reports Q3 EPS $1.79, consensus $1.41
- 02/01/23
- Thermo Fisher sees Q1 EPS over 20% of full-year total, consensus $5.41
- 02/01/23
- Thermo Fisher sees FY23 adjusted EPS $23.70, consensus $23.21
- 02/01/23
- Thermo Fisher reports Q4 adjusted EPS $5.40, consensus $5.19
- 01/31/23
- Notable companies reporting before tomorrow's open
- 03/21/23
- Tencent Music reports Q4 EPS 11c, consensus 13c
- 11/15/22
- Tencent Music reports Q3 EPS 12c, consensus 10c
- 01/09/23
- Tilray reports Q2 adjusted EPS (6c) vs. (8c) last year
- 10/07/22
- Tilray reports Q1 adjusted EPS (8c) vs. (13c) last year
- 03/15/23
- Royalty Pharma raises FY23 adjusted cash receipt guidance to $2.85B-$2.95B
- 01/31/23
- Pfizer sees FY23 adjusted EPS $3.25-$3.45, consensus $4.44
- 01/31/23
- Pfizer reports Q4 adjusted EPS $1.14, consensus $1.05
- 01/30/23
- Notable companies reporting before tomorrow's open
- 03/20/23
- Pinduoduo reports Q4 adjusted EPS $1.21, consensus $1.21
- 11/28/22
- Pinduoduo reports Q3 adjusted EPS $1.21, consensus 65c
- 03/21/23
- On Holding sees FY23 revenue of 'at least' CHF 1.7B vs. CHF 1.22B last year
- 03/21/23
- On Holding reports Q4 EPS CHF0.02 vs. (CHF0.04) last year
- 11/16/22
- On Holding raises FY22 revenue view to CHF 1.125B from CHF 1.1B
- 11/16/22
- On Holding reports Q3 EPS CHF0.06 vs. CHF0.04 last year
- 02/22/23
- Nvidia sees Q1 revenue $6.5B plus of minus 2%, consensus $6.33B
- 02/22/23
- Nvidia reports Q4 EPS 88c, consensus 81c
- 02/22/23
- Notable companies reporting after market close
- 11/16/22
- Nvidia sees Q4 revenue $6B, +/- 2%, consensus $6.09B
- 02/23/23
- Moderna reports Q4 EPS $3.61, consensus $4.67
- 02/22/23
- Notable companies reporting before tomorrow's open
- 11/03/22
- Moderna reports Q3 EPS $2.53, consensus $3.29
- 02/01/23
- Meta Platforms sees Q1 revenue $26B-$28.5B, consensus $27.14B
- 02/01/23
- Meta Platforms reports Q4 EPS $1.76, consensus $2.22
- 02/01/23
- Notable companies reporting after market close
- 11/09/22
- Meta Platforms backs Q4 revenue outlook $30B-$32.5B, consensus $31.52B
- 03/21/23
- LumiraDx reports Q4 adjusted EPS (12c), consensus (20c)
- 11/09/22
- LumiraDx reports Q3 EPS (47c), consensus (26c)
- 01/26/23
- Knight-Swift sees FY23 EPS $4.05-$4.25, consensus $4.16
- 01/26/23
- Knight-Swift reports Q4 EPS $1.00, consensus $1.12
- 10/19/22
- Knight-Swift cuts FY22 EPS view to $5.17-$5.22 from $5.30-$5.45 prior
- 10/19/22
- Knight-Swift reports Q3 adjusted EPS $1.27, consensus $1.32
- 03/21/23
- Huya reports Q4 EPS (26c), consensus (30c)
- 11/15/22
- Huya reports Q3 EPS 6c, consensus (3c)
- 02/02/23
- Harley-Davidson reports Q4 EPS 28c, consensus 6c
- 10/26/22
- Harley-Davidson reaffirms FY22 revenue view increase 5%-10%
- 10/26/22
- Harley-Davidson reports Q3 GAAP EPS $1.78, consensus $1.40
- 10/25/22
- Notable companies reporting before tomorrow's open
- 01/30/23
- Harmonic sees FY23 non-GAAP EPS 56c-72c, consensus 74c
- 01/30/23
- Harmonic sees Q1 non-GAAP EPS 7c-10c, consensus 10c
- 01/30/23
- Harmonic reports Q4 non-GAAP EPS 17c, consensus 14c
- 10/31/22
- Harmonic reports Q3 non-GAAP EPS 13c, consensus 10c
- 02/02/23
- Alphabet reports Q4 EPS $1.05, consensus $1.18
- 02/02/23
- Notable companies reporting after market close
- 10/25/22
- Alphabet reports Q3 EPS $1.06, consensus $1.25
- 10/25/22
- Notable companies reporting after market close
- 02/14/23
- GoDaddy sees FY23 revenue $4.25B-$4.325B, consensus $4.35B
- 02/14/23
- GoDaddy sees Q1 revenue $1.03B-$1.05B, consensus $1.05B
- 02/14/23
- GoDaddy reports Q4 EPS 60c, consensus 62c
- 02/14/23
- Notable companies reporting after market close
- 03/20/23
- Foot Locker targeting adjusted EPS growth in low to mid 20% range for FY24-FY26
- 03/20/23
- Foot Locker sees FY23 adjusted EPS $3.35-$3.65, consensus $4.48
- 03/20/23
- Foot Locker reports Q4 adjusted EPS 97c, consensus 51c
- 11/18/22
- Foot Locker raises FY22 EPS view to $4.42-$4.50 from $4.25-$4.45
- 03/21/23
- Canadian Solar sees FY23 revenue $8.5B-$9.5B, consensus $9.88B
- 03/21/23
- Canadian Solar sees Q1 revenue $1.6B-$1.8B, consensus $1.95B
- 03/21/23
- Canadian Solar reports Q4 EPS $1.11, consensus 76c
- 02/24/23
- Canadian Solar sees Q1 revenue $1.6B_$1.8B, consensus $2.04B
- 02/09/23
- Credit Suisse reports Q4 net revenue CHF 3.06B vs. CHF 4.58B last year
- 10/27/22
- Credit Suisse reports Q3 net revenue CHF 3.8B vs. CHF 5.43B last year
- 02/09/23
- Canopy Growth reports Q3 EPS (C$0.54) vs. (C$0.28) a year ago
- 11/09/22
- Canopy Growth reports Q2 adjusted EBITDA (C$78.1M), up 52% y/y
- 10/06/22
- Constellation Brands reports Q2 comparable EPS ex-Canopy losses $3.33
- 11/07/22
- BioNTech reports Q3 EPS EUR 6.98 vs. EUR 12.35 last year
- 03/07/23
- BlackBerry sees FY23 revenue $656M, consensus $674.73M
- 03/07/23
- BlackBerry reports preliminary Q4 revenue $151M, consensus $168.45M
- 12/20/22
- BlackBerry reports Q3 adjusted EPS (5c), consensus (7c)
- 09/27/22
- BlackBerry reports Q2 EPS (5c), consensus (7c)
- 02/09/23
- Baxter sees FY23 adjusted EPS $2.75-$2,95, consensus $3.56
- 02/09/23
- Baxter sees Q1 adjusted EPS 46c-50c, consensus 76c
- 02/09/23
- Baxter reports Q4 adjusted EPS 88c, consensus 94c
- 02/08/23
- Notable companies reporting before tomorrow's open
- 02/21/23
- Armstrong World sees FY23 adjusted EPS $4.80-$5.05, consensus $5.25
- 02/21/23
- Armstrong World reports Q4 adjusted EPS $1.08, consensus $1.12
- 10/25/22
- Armstrong World lowers 2022 adjusted EPS view to $4.75-$4.85 from $5.10-$5.20
- 10/25/22
- Armstrong World reports Q3 adjusted EPS $1.36, consensus $1.47
- 02/28/23
- Altimmune reports Q4 EPS (43c), consensus (50c)
- 11/10/22
- Altimmune reports Q3 EPS (48c), consensus (50c)
- 03/21/23
- ProFrac Holding reports Q4 EPS 82c, consensus 88c
- 11/10/22
- ProFrac Holding sees Q4 revenue above Q3, consensus $755.54M
- 11/10/22
- ProFrac Holding reports Q3 EPS $1.09, consensus 86c
|